Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-05-17
2011-05-17
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388250, C530S391100, C424S130100, C424S142100, C424S178100, C435S069600
Reexamination Certificate
active
07943745
ABSTRACT:
A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.
REFERENCES:
patent: 7326414 (2008-02-01), Bedian et al.
patent: 7498420 (2009-03-01), Michaud et al.
patent: 1 111 048 (2001-06-01), None
patent: 2000-157286 (2000-06-01), None
patent: WO 02/43478 (2002-06-01), None
patent: WO 03/001884 (2003-01-01), None
patent: WO 2004/035607 (2004-04-01), None
patent: WO 2008/017828 (2008-02-01), None
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1452.
Rudikoff, Giusti, Cook and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen binding site of an anti-ErbB2 antibody obtained by shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Schwartz, G.P., Burke, G.T., and Katsoyannis, P.G. A superactive insulin: [B10-Aspartic acid]insulin (human). Proceedings of the National Academy of Sciences, 1987. vol. 84, pp. 6408-6411.
Lin, M.C., Wright, D.E., Hruby, V.J., and Rodbell, M. Structure-function relationships in glucagon: properties of highly purified Des-His1- Monoiodo-, and [Des-Asn28, Thr29](homoserine lactone27)glucagon. Biochemistry, 1975. vol. 14, pp. 1559-1563.
Acland, Dixon, Peters, and Dickson. Subcellular fate of the Int-2 oncoprotein is determined by choice of initiation codon. Nature, 1990. vol. 343, pp. 662-665.
Verma and Somia. Gene therapy—promises, problems, and prospects. Nature, 1997. vol. 389, pp. 239-242.
Pfeifer and Verma. Gene therapy: promises and problems. Annual Reviews in Genomics and Human Genetics, 2001. vol. 2, pp. 177-211.
Kelland. “Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug development. European Journal of Cancer, 2004. vol. 40, pp. 827-836.
Eck and Wilson. Gene Based Therapy. Goodman & Gilman, eds. The Pharmacological basis of Therapeutics, 1996. McGraw-Hill, New York, NY. pp. 77-101.
Granziero, Krajewski, Farness, Yuan, Courtney, Jackson, Peterson, and Vitiello. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. European Journal of Immunology, 1999. vol. 29, pp. 1127-1138.
Byers. What can randomized controlled trials tell us about nutrition and cancer prevention? CA Cancer Journal Clin. 1999. vol. 49, pp. 353-361.
Osamu Yanagida et al., “Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines”, Biochimica et Biophysica Acta 1514 (2001) 291-302.
Eijiro Nakamura et al., “4F2 (CD98) Heavy Chain Is Associated Covalently with an Amino Acid Transporter and Controls Intracellular Trafficking and Membrane Topology of 4F2 Heterodimer”, The Journal of Biological Chemistry, vol. 274, No. 5, Issue of Jan. 29, 1999, pp. 3009-3016.
Kaori Hara et al., “Malignant Transformation of NIH3T3 Cells by Overexpression of Early Lymphocyte Activation Antigen CD98”, Biochemical and Biophysical Research Communications 262, 720-725, 1999.
Kaori Hara et al., “Enhanced tumorigenicity caused by truncation of the extracellular domain of GP125/CD98 heavy chain”, Oncogene (2000) 19, 6209-6215.
Tsuroka, et al., “Characterization of Human IgG Recognizing Intracellular CD98hc Epitope,” Proceedings of the 63rdAnnual Meeting of the Japanese Cancer Association, Sep. 29-Oct. 1, 2004, Fukuoka, Japan,Cancer Science, vol. 95 Supplement, 2004, p. 310, p. 0808. (English Translation provided).
Tsuroka, et al., “Characterization of Human IgG Recognizing Intracellular CD98hc Epitope,” Proceedings of the 63rdAnnual Meeting of the Japanese Cancer Association, Sep. 29-Oct. 1, 2004, Fukuoka, Japan,Cancer Science, vol. 95 Supplement, 2004, p. 310, p. 0808.
Supplementary European Search Report EP 07 74 1116 dated Feb. 17, 2010.
Hiroshi Nawashiro et al., “The Role of CD98 in Astrocytic Neoplasms”, Human Cell, vol. 15, No. 1, (2002), pp. 25-31.
Do Kyung Kim et al., “Expression of L-type Amino Acid Transporter 1 (LAT1) and 4F2 Heavy Chain (4F2hc) in Oral Squamos Cell Carcinoma and it's Precursor Lesions”, Anticancer Research 24: 16741-1676 (2004).
Endou Hitoshi
Hasegawa Kazumasa
Kanai Yoshikatsu
Kataoka Shiro
Tahara Tomoyuki
Bent Stephen A.
Foley & Lardner LLP
Gussow Anne M.
Kyowa Hakko Kirin Co., Ltd.
LandOfFree
Anti-CD98 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CD98 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD98 antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2686913